Bexsero, the vaccine against meningococcal group B (MenB) developed by Novartis, has won the Innovative Product Award at the UK Prix Galien Awards - the Oscars of the pharmaceutical world. Our CEO Sue joined experts from Novartis at the awards at the Houses of Commons on Wednesday night. With vaccine the only way to prevent meningitis, we are delighted that the first vaccine against MenB has been recognised in this way and offer our congratulations to team behind it. It has taken more than 20 years of research and development to develop this vaccine, now licensed for use in the UK. The vaccine was recommended for introduction into the childhood immunisation programme by the Joint Committee of Vaccination and Immunisation in March this year, subject to a cost effective price being agreed, but we are still waiting to hear when it will be introduced. Time lost is lives lost and we hope to hear very soon that negotiations have been completed and the vaccine will be introduced”.
Posted on: Thu, 02 Oct 2014 19:05:01 +0000
Trending Topics
Recently Viewed Topics
© 2015